New Two-Drug combo tested for advanced melanoma in india
NCT ID NCT07459543
Summary
This study is testing the safety and effectiveness of a two-drug combination (nivolumab + relatlimab) for people in India with advanced melanoma that cannot be removed by surgery or has spread. The study will enroll 30 participants who have not received any prior treatment for their advanced melanoma. Researchers will monitor side effects and see how well the treatment shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Local Institution - 0001
New Delhi, 110085, India
Contact
-
Local Institution - 0002
Chennai, 600006, India
Contact
-
Local Institution - 0003
Bhubaneswar, Odisha, 751007, India
Contact
-
Local Institution - 0004
New Delhi, 110029, India
Contact
-
Local Institution - 0005
Nagpur, 440001, India
Contact
-
Local Institution - 0006
Mumbai, 400 012, India
Contact
-
Local Institution - 0008
Pune, Maharashtra, 411017, India
Contact
-
Local Institution - 0009
Navi Mumbai, Maharashtra, 400614, India
Contact
Conditions
Explore the condition pages connected to this study.